Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease.
In: Pharma Business Week, 2024-03-12, S. 2047-2047
serialPeriodical
Zugriff:
Skyhawk Therapeutics, a biotechnology company, has entered the multiple ascending dose portion of its Phase 1 clinical study for SKY-0515, a small molecule drug targeting Huntington's disease. Huntington's disease is caused by a mutation in the huntingtin gene, resulting in the production of a toxic protein. SKY-0515 aims to modify the RNA expression of the gene, reducing the production of the mutated protein. This clinical trial is the first for a drug developed by Skyhawk Therapeutics and aims to investigate the safety and efficacy of SKY-0515 in healthy volunteers and Huntington's patients. [Extracted from the article]
Copyright of Pharma Business Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease.
|
---|---|
Zeitschrift: | Pharma Business Week, 2024-03-12, S. 2047-2047 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6675 (print) |
Schlagwort: |
|
Sonstiges: |
|